SELLAS (SLS) appoints Linghua Wang to scientific advisory board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
July 7, 2025 8:45 AM EDTNEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (SELLAS or the Company), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Companys SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD.
We are thrilled to welcome Dr. Wang to our... More
